Being able to test newly synthesized molecules is a pivotal part of early-stage drug discovery, with the data from assays driving decisions on the next molecules to be developed. The Creoptix WAVE with waveRAPID technology enables testing of full kinetic parameters for up to 400 compound fragments unattended in a 24-hour period.
Trevor Askwith presents how Domainex is using waveRAPID to accelerate the analog expansion to support our fragment and virtual screening hit ID platforms.